Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target

Benzinga · 08/30 15:58
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $23 price target.